Abstract: An electronic switch includes a load path connected in series with the load and a drive terminal for receiving a drive signal. The electronic switch is operable to switch between a first operation state and a second operation state dependent on the drive signal. In a first switching cycle, the electronic switch is switched from the first operation state to the second operation state and a voltage across the load is evaluated during the first switching cycle in order to obtain a measured switching profile. The measured switching profile is compared with a reference profile. A drive profile dependent on the comparison is provided. The drive profile is used to drive the electronic switch in a second switching cycle after the first switching cycle. At least two drive parameters are used at different times in the at least one second switching cycle to drive the electronic switch.

Abstract: Provided is a method for characterizing a molecule by mass spectrometry, which molecule comprises one or more free amino groups, which method comprises: (a) reacting one or more free amino groups in the molecule with a mass tag reagent comprising a reactive functionality capable of reacting with an amino group, and a tertiary amino group linked to the reactive functionality; and (b) characterizing the molecule by mass spectrometry.

Abstract: A process for the preparation of a compound of formula (I): which is useful as an intermediate in the preparation of pharmaceutically active compounds.

Abstract: Methods and compositions relating to Alzheimer's disease are provided. Specifically, proteins that are differentially expressed in the Alzheimer's disease state relative to their expression in the normal state are provided. Proteins associated with Alzheimer's disease are identified and described. Methods of diagnosis of Alzheimer's disease using the differentially expressed proteins are also provided, as are methods for the identification and therapeutic use of compounds for the prevention and treatment of Alzheimer's disease.

Abstract: Methods and compositions relating to Alzheimer's disease are provided. Specifically, proteins that are differentially expressed in the Alzheimer's disease state relative to their expression in the normal state are provided. Proteins associated with Alzheimer's disease are identified and described. Methods of diagnosis of Alzheimer's disease using the differentially expressed proteins are also provided, as are methods for the identification and therapeutic use of compounds for the prevention and treatment of Alzheimer's disease.

Abstract: A method is provided that comprises determining an amount of a first current from an amount of a charge stored in a first capacitor. Also, an apparatus is provided that comprises a reference timer circuit configured to generate a first signal indicating an expiration of a time period, and a sense circuit comprising a first capacitor and configured to sense, responsive to the first signal, a charge stored in the first capacitor, and to generate a second signal representing the sensed charge.

Abstract: A mass label for labelling and detecting a biological molecule by mass spectroscopy, which label comprises the following structure: X-L-M wherein X is a mass marker moiety comprising the following group: formula (I), wherein the cyclic unit is aromatic or aliphatic and comprises from 0-3 double bonds independently between any two adjacent atoms; each Z is independently N, N(R1), C(R1), CO, CO(R1), C(R1)2, O or S; X is N, C or C(R1); each R1 is independently H, a substituted or unsubstituted straight or branched C1-C6 alkyl group, a substituted or unsubstituted aliphatic cyclic group, a substituted or unsubstituted aromatic group or a substituted or unsubstituted heterocyclic group; and y is an integer from 0-10, L is a cleavable linker comprising an amide bond and M is a mass normalization moiety.

Abstract: Provided is a set of mass labels, each mass label in the set comprising a mass marker moiety attached via a cleavable linker to a mass normalisation moiety, each mass label in the set having a common mass; wherein the set comprises a plurality of groups of mass labels, the mass of the mass marker moiety being the same for mass labels within a group, the mass of the mass marker moiety being different between groups; the mass marker moiety is capable of fragmentation into two or three fragments; and the mass of at least one fragment of the mass marker moiety differs between mass labels within a group.

Abstract: The invention relates to a method of diagnosis of colorectal cancer in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an increased concentration of a protein in the diagnostic sample, compared with a control, normal human sample, the protein being: transforming growth factor-beta induced protein IG-H3 (SwissProt Acc. No. Q15582); suppressor of G2 allele of SKP1 homolog (isoform 2) (SwissProt Acc. No. Q9Y2Z0-2); hypothetical protein (part of URG4) (SwissProt Acc. No. Q9NWR7); calponin-2 (SwissProt Acc. No. Q99439); heat shock protein HSP90-beta (SwissProt Acc. No. P08238); phosphoglycerate mutase 1 (SwissProt Acc. No. P18669); serpin Cl protein (SwissProt Acc. No. P01008); or haptoglobin precursor (SwissProt Acc. No. P00738); or a decreased concentration of a protein in the diagnostic sample, compared with a control, normal human sample, the protein being serotransferrin (SwissProt Acc. No. P02787); 26S proteasome subunit p40.5 (Swiss Prot Acc. No.

Abstract: A method is provided that comprises determining an amount of a first current from an amount of a charge stored in a first capacitor. Also, an apparatus is provided that comprises a reference timer circuit configured to generate a first signal indicating an expiration of a time period, and a sense circuit comprising a first capacitor and configured to sense, responsive to the first signal, a charge stored in the first capacitor, and to generate a second signal representing the sensed charge.

Abstract: Methods and compositions relating to Alzheimer's disease are provided. Specifically, proteins that are differentially expressed in the Alzheimer's disease state relative to their expression in the normal state are provided. Proteins associated with Alzheimer's disease are identified and described. Methods of diagnosis of Alzheimer's disease using the differentially expressed proteins are also provided, as are methods for the identification and therapeutic use of compounds for the prevention and treatment of Alzheimer's disease.

Abstract: Provided is a method for characterising a molecule by mass spectrometry, which molecule comprises one or more free amino groups, which method comprises: (a) reacting one or more free amino groups in the molecule with a mass tag reagent comprising a reactive functionality capable of reacting with an amino group, and a tertiary amino group linked to the reactive functionality; and (b) characterising the molecule by mass spectrometry.

Abstract: The invention relates to a process for preparing hydroxyindolylglyoxylamides in high yields and particularly pure form.

Abstract: A unit carrier for secondary units of a motor vehicle internal combustion engine, having secondary unit attachment devices and engine block attachment devices. The unit carrier has a planned deformation point, which allows a relative displacement between the secondary unit and the engine block in case of a vehicle collision, if a predefined force is exceeded. The unit carrier is used in motor vehicles having a front engine arrangement.

Abstract: The invention relates to novel modifications of the compound 2-amino-4-(4-fluorobenzylamino)-1-ethoxy-carbonylaminobenzene of the processes for their preparation and their use in pharmaceutical compositions.